Parkinson’s Disease Serum
About: Parkinson's Disease Serum - Human serum samples collected from clinically confirmed Parkinson's Disease donors. Ideal for identifying and characterizing protein biomarkers, inflammatory mediators, and oxidative stress markers.
| Lot Number | Condition | Volume | Race/Ethnicity | Age | Gender | Country of Collection | Medications | Vials | Price | Action |
|---|---|---|---|---|---|---|---|---|---|---|
| 72958 | Parkinson's Disease | 1.0 ML | Caucasian | 55 | Female |
Carvidopa Levedopa/ 100mg/25mg 4x QID Gabapentin Lexapro 20mg QD Neurontin /300mg/QN
|
8 | $495.00 | ||
| 73116 | Parkinson's Disease | 1.0 ML | Caucasian | 59 | Male |
Xadago 100 mg QD Rytary
|
8 | $495.00 | ||
| 72905 | Parkinson's Disease | 1.0 ML | Caucasian | 68 | Male |
Zoloft 100 mg QD Tricor 120 mg QD Amantadine 100 mg BID Valsartan 80 mg QD Sinemet 200 mg BID
|
8 | $495.00 | ||
| 72955 | Parkinson's Disease | 1.0 ML | Caucasian | 78 | Male |
Extended release Carbidopa / Levodopa/2500mg/QID Tamsulosin/0.4mg/QD SAW PALMETTO/450mg/QD VIt D QW Vit C
|
8 | $495.00 | ||
| 69859 | Parkinson's Disease | 1.0 ML | Caucasian | 66 | Male |
Stelivo 125mg TID Azilect 1 mg QD Neupro Patch 6 mg QD Vitamin C/QD Vitamin D/QD
|
8 | $495.00 | ||
| 73019 | Parkinson's Disease | 1.0 ML | Caucasian | 70 | Female |
Carbidopa/Levodopa 25/100 IR 10 tabs po QD Carbidopa/Levodopa 25/100 ER 2 tabs po QHS Selegiline 5 mg po QD Paroxetine HCL 30 mg po QD Levothyroxine 0.75 mcg po QD Fluocinolone Acetonide Cream QD Fluocinonide Topical solution PRN Restasis BID Clobetasol Propionate Cream Weekly Vitamin D3 2000 IU po QD Multivitamin po QD Melatonin 10 mg Tylenol PRN
|
8 | $495.00 | ||
| 72951 | Parkinson's Disease | 1.0 ML | Caucasian | 57 | Female |
Semaglutide/40grams/week Carbidopa Levedopa 25mg / 100mg QID Nupro Patch / 6mg Valtrex prn
|
8 | $495.00 | ||
| 69324 | Parkinson's Disease | 1.0 ML | Asian/Pacific Islander | 63 | Male |
Rytary 3 caps Q4H + 2 extra tabs in am Ropinirole 3 mg TID Selegiline 5 mg BID Amantadine 100 mg BID Flomx 0.4 mg 2 caps QD Kynmobi 30 mg SL patch
|
8 | $495.00 | ||
| 69267 | Parkinson's Disease | 1.0 ML | Caucasian | 71 | Male |
Rosuvastatin 10 mg QD Cyclobenzaprine 5 mg TID PRN Indonethacin 50 mg BID Carbidopa/Levidopa 8 tabs per day Donepezil 5 mg QD Glycopyrrolate 1 mg TID PRN Entacapone 200 mg QD Vit D QW Levothyroxine 125 mcg QD Ciclopirox PRN
|
8 | $495.00 | ||
| 68932 | Parkinson's Disease | 1.0 ML | Caucasian | 72 | Female |
Levothyroxine 50 QD Pramipexole 1.5mg TID Carbidopa levodopa 25/100mg TID gocovri 137mg QHS duloxetine 30mg QD atorvastatin 20mg QD moloxicam .25mg QD Atenolol 25mg DQ
|
8 | $495.00 |
Human Parkinson’s Disease Serum for Research
Our Parkinson’s Disease Serum is sourced from IRB-consented donors clinically diagnosed with Parkinson’s Disease. Each sample is processed and frozen within 24 hours of collection to ensure consistency and high quality for protein biomarkers, inflammatory mediators, and oxidative stress markers to characterize disease status and progression.
Product Features
- Collected from clinically confirmed Parkinson’s Disease donors
- Research Use Only (RUO)
- IRB-approved protocols with documented consent
De-identified Donor Data
- Diagnosis confirmation
- Age, sex assigned at birth, and ethnicity
- Donor-reported allergy and infectious disease history
Applications
- Biomarker discovery for Parkinson’s Disease
- Serum cytokine and protein profiling
- Therapeutic candidate screening and validation
Compliance and Quality Assurance
- IRB-approved and HIPAA-compliant protocols
- Electronic informed consent with 21 CFR Part 11 – compliant e-signatures
- Documentation support available for regulatory review
Ordering and Customization
Parkinson’s Disease serum is available in standard and custom volumes. For international orders or documentation requirements, please email learnmore@sanguinebio.com to ensure compatibility with your country’s regulations.
Protocols & Documentation
-
Download
Serum Isolation
Protocol for serum preparation from whole blood, including collection handling, clarification, and quality documentation.
-
Informed Consent Form (ICF)
Available upon request — confirms donor consent for research use and downstream commercialization.
Parkinson's Disease Publications
Serum
Frequently Asked Questions
1 Answer
YES – All collections are conducted under IRB-approved protocols and electronic informed consent. Sanguine utilizes Advarra and WCG IRB for oversight.
1 Answer
YES – with the exception of GMP leukopaks, all our products are research use only (RUO).
1 Answer
Our complete catalog can be found here: https://sanguinebio.com/products/
1 Answer
Storage depends on sample type but often cryopreserved samples stored in liquid nitrogen can be stored for years.
1 Answer
Extensive customization is available. To discuss your project request a quote or email us at learnmore@sanguinebio.com.
1 Answer
Sanguine offers flexible prospective colleciton services to tailored to fit your research. For more information and request a quote, please see: https://sanguinebio.com/prospective-biospecimen-collection-services/
1 Answer
Timelines depend on condition, sample type, and I/E criteria but we often start collection within 2 weeks of signed agreement.
1 Answer
YES – we have in-stock inventory which can be found here https://sanguinebio.com/products/?pro_inventory=inventory. You can also email us at learnmore@sanguinebio.com as we continually get new samples in our inventory.
1 Answer
Each sample from a different individual – Unique donor means each sample comes from a different person, ensuring biological diversity in your study.
1 Answer
YES – Unique donors can be specified and guaranteed based on your requirements.
1 Answer
For information about sample quality, please see: https://sanguinebio.com/quality-and-compliance/
1 Answer
YES – “IRB-approved collection protocols” and IRB approval documentation available upon request. Sanguine utilizes two internationally-recognized IRBs (Advarra and WCG IRB) for review and approval.
Ask a Question
Need a custom Serum cohort?
Our scientific team can scope prospective collections with donor-specific I/E criteria, typically starting within 2 weeks of agreement.